Danaher Corporation (DHR) - Stock Report

Recherche informative — ne constitue pas un conseil en investissement.Avertissement complet

Recherche informative — ne constitue pas un conseil en investissement. Générée en partie par IA et peut contenir des erreurs ; ce n'est pas une recommandation personnalisée, une sollicitation ni une offre. ReasyPort n'est pas une entreprise d'investissement agréée ou réglementée. Les données de marché peuvent être différées ou inexactes. Le capital est à risque et les performances passées ne préjugent pas des résultats futurs — faites vos propres recherches et consultez un conseiller agréé.

Avertissement complet
DHR

Danaher Corporation

ReasyPort View: Too Demanding — Core Growth And Margin Proof Required

Summary

Danaher is a high-quality life-science tools and diagnostics cash-conversion platform, but the 18 June 2026 market snapshot price of $177.17 sits about 32% above the selected DCF fair value of $134.45. The DCF range runs from a $107.33 downside marker to a $166.82 upside marker, so the stock trades about 6.2% above the entire underwritten range — selected case and upside marker alike. The premium is not absurd for a franchise of this calibre, but it asks investors to fund a higher durable cash base than reported core growth and margin yet support; this is a price-discipline verdict on a dominant compounder, not a weak-business verdict and not a short thesis. The market may be underwriting a cleaner bioprocessing recovery, stronger Diagnostics normalization, and Masimo execution before those items are fully visible in reported core growth. That is a defensible debate for a business with Danaher's history, but it puts the burden on segment margin recovery and post-capex cash conversion to prove that the intrinsic-value anchor should move up. The key macro issue is not healthcare demand in abstract, but whether the biopharma inventory and capex cycle flows through Danaher’s Biotechnology consumables into core growth, reported margin and post-capex free cash flow; if it does, Masimo funding can be absorbed, but if it does not, Diagnostics seasonality and integration costs make the premium multiple harder to defend.

Latest Proof Snapshot

The latest proof is mixed. In fiscal Q1 2026, reported revenue rose 3.5% to $5.951bn, company-defined core revenue increased only 0.5%, reported net earnings were $1.029bn, reported diluted EPS was $1.45, and adjusted diluted EPS rose 9.5% to $2.06; that adjusted EPS bridge adds back $434m pretax, or $360m after tax, of acquisition-related intangible amortization, $77m pretax, or $59m after tax, of equity and limited-partnership investment fair-value losses, plus $17m pretax, or $15m after tax, of Masimo transaction costs. Those investment losses are not operating segment economics, so the cash proof matters more than the adjusted headline alone. Management's guide is the live test: Q2 company-defined core revenue is expected to increase in the low-single-digit range, and full-year 2026 company-defined core revenue is still expected to grow 3% to 6%, with adjusted diluted EPS guidance raised to $8.35-$8.55. Operating cash flow for the quarter was $1.322bn and company-reported free cash flow for the quarter was $1.085bn, so the cash signal was solid; it should not be annualized mechanically because the same release cited a lighter-than-typical Cepheid respiratory season and a still-gradual recovery path.

Business Overview

What The Company Actually Does

Danaher is no longer best read as a diversified industrial conglomerate. After the Veralto separation, it is a healthcare and life-science tools platform organized around Biotechnology, Life Sciences, and Diagnostics. It sells instruments, reagents, consumables, software, services, and workflow systems to biopharma manufacturers, research labs, hospitals, and clinical diagnostic customers.

How The Business Is Organized

The value stack is not the hardware alone. Biotechnology provides bioprocessing workflows and consumables that follow drug developers from process development into validated production. Life Sciences supplies analytical instruments, microscopy, genomics, and lab workflow tools that benefit when research budgets and pharma investment normalize. Diagnostics carries clinical-testing platforms, including Cepheid molecular diagnostics, where installed instruments can drive recurring test volumes but are exposed to respiratory-season variability and hospital-budget discipline.

What Management Appears To Be Prioritizing

Danaher Business System is the operating method that ties these assets together. Its role is to turn specialized scientific franchises into measurable productivity, pricing, quality, and acquisition-integration gains. The test is whether that system converts the current recovery into durable core revenue growth and margin expansion, rather than merely protecting adjusted EPS during a softer funding cycle.

🔒

Connectez-vous pour lire le rapport complet

Créez un compte gratuit pour débloquer le reste de ce rapport et accéder à toute notre bibliothèque.